Table S2 from Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

Lozada, John R.; Elliott, Andrew; Evans, Mark G.; Wacker, James; Storey, Kathleen M.; Egusa, Emily A.; Zorko, Nicholas A.; Kumar, Akhilesh; Crymes, Anthony; Heath, Elisabeth I.; Carneiro, Benedito A.; Soares, Heloisa P.; Cichocki, Frank; Miller, Jeffrey S.; Lou, Emil; Beltran, Himisha; Antonarakis, Emmanuel S.; Ryan, Charles J.; Hwang, Justin H.

doi:10.1158/2767-9764.28417558

Table S2 from Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

https://doi.org/10.1158/2767-9764.28417558

journal contribution

posted on 2025-02-14, 12:20 authored by John R. Lozada, Andrew Elliott, Mark G. Evans, James Wacker, Kathleen M. Storey, Emily A. Egusa, Nicholas A. Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I. Heath, Benedito A. Carneiro, Heloisa P. Soares, Frank Cichocki, Jeffrey S. Miller, Emil Lou, Himisha Beltran, Emmanuel S. Antonarakis, Charles J. Ryan, Justin H. Hwang

<p>DLL3-high versus -low hazard ratios across cancer.</p>

History

Related Materials

1.
DOI - Is supplement to Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

ARTICLE ABSTRACT

DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.

Usage metrics

Keywords

Drug Targets Gene Technologies High-throughput sequencing Gene Expression Profiling Precision Medicine Translational Research

Licence

CC BY

Table S2 from Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

History

Related Materials

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports